Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: A prospective study

Leukemia

Volumn 16, Issue 4, 2002, Pages 587-593

  Lefrere F ^a   Delmer, A ^b   Suzan, F ^c   Levy, V ^d   Belanger, C ^a   Djabarri, M ^e   Arnulf, B ^a   Damaj, G ^a   Maillard, N ^a   Ribrag, V ^f   Janvier, M ^g   Sebban, C ^h   Casasnovas, R O ⁱ   Bouabdallah, R ^j   Dreyfus, F ^e   Verkarre, V ^a   Delabesse, E ^a   Valensi, F ^a   McIntyre, E ^a   Brousse, N ^a   Varet, B ^a   Hermine, O ^a   more..

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b HÔTEL DIEU   (France)

^c CENTRE HOSPITALIER DE VERSAILLES   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e Hôpital Cochin ^*  (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g CENTRE RENÉ HUGUENIN   (France)

^h EDOUARD HERRIOT HOSPITAL   (France)

ⁱ DIJON UNIVERSITY HOSPITAL   (France)

^j INSTITUT PAOLI CALMETTES   (France)

more..

Author keywords

Autograft; CHOP; DHAP; Mantle cell lymphoma; Total body irradiation

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADULT; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA REMISSION; MALE; MANTLE CELL LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; SEPSIS; SIDE EFFECT; WHOLE BODY RADIATION;

EID: 85014234123     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402406     Document Type: Review

References (29)

1. Report of the workshop on mantle cell lymphoma (MCL)
2. A revised European-American classification of lymphoid neoplam: A proposal from the International Lymphoma Study Group
3. Mantle cell lymphoma - An entity comes of age
4. Detection of chromosome 11 alterations in blood and bone marrow by interphase cytogenetics in mantle cell lymphoma
5. Detection of cyclin D1 overexpression by a simple competitive reverse transcription-polymerase chain reaction assay in t(11;14)-bearing B-cell malignancies and/or mantle cell lymphoma
6. Cyclin D1 overexpression allows identification of an aggressive subset of leukemic lymphoproliferative disorder
7. Quantitative RNA slot-blot analysis of CCND1/cyclin D1 expression in suspected mantle cell lymphoma
8. Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative group subtype according to the revised European-American classification of comparison with the Working Formulation
9. Mantle cell lymphoma: Presenting features, response to therapy, and prognosis factors
10. The clinical outcome of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group
11. CD5-expressing B cell non Hodgkin's lymphomas with bcl-1 gene rearrangement have a relatively homogeneous immunophenotype and are associated with an overall poor prognosis
12. A clinical analysis of the two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories)
13. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis
14. High-dose therapy with stem cell transplantation for mantle cell lymphoma: Results and prognostic factors, a single center experience
15. The TAM regimen, prior to allogenic and autologous bone marrow transplantation for high-risk acute lymphoblastic leukemias: A cooperative study of 62 patients
16. Report on the committee on Hodgkin's disease staging classification
17. Homing receptor alpha4beta7 integrin expression predicts digestive tract involvement in mantle cell lymphoma
18. Mantle cell lymphoma: Correlation of clinical outcome and biologic features with three histologic variants
19. Nonparametric estimation from incomplete observations
20. A predictive model for aggressive non-Hodgkin's lymphoma. The International non-Hodgkin's lymphoma prognostic factors
21. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: Clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes
22. Mantle cell lymphoma: A retrospective study of 121 cases
23. Treatment of mantle cell-lymphoma with the VAD +/- chlorambucil regimen with or without subsequent high dose therapy and peripheral blood stem cell transplantation
24. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine and cisplatin before marrow transplantation
25. Effective therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
26. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem cell transplantation: An active regimen for aggressive mantle-cell lymphoma
27. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting
28. Treatment of mantle cell lymphoma with Rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle cell lymphoma and previously treated mantle cell lymphoma, immunocytoma and small lymphocytic lymphoma
29. Preliminary report of Rituximab with intensive chemotherapy for untreated aggressive mantle cell lymphoma